Brophy Michael Burkes sold $1.3M of NTRA

Brophy Michael Burkes (CHIEF FINANCIAL OFFICER) sold 3,084 shares of Natera, Inc. (NTRA) at an average of $425.90 ($425.32–$426.87, $1.31M total) across 3 trades over 2026-10-28 to 2026-10-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brophy Michael Burkes
Published Oct 31, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 31, 2026, 2:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

A CFO sale, even modest, can be interpreted as a lack of confidence, prompting short interest.

02

Market read

Primary insider sale filing; modest relevance for short‑term traders.

03

What to watch

Potential tax planning or diversification motives may mitigate negative signal.

Relevance 5/10Novelty 3/10Timing: after-hours filing on 2026-10-30

Background

SEC Form 4 filing discloses insider transactions; investors monitor such sales for signals.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

CFO Brophy Michael Burkes sold 3,084 shares for $1.3M via a 10b5‑1 plan, reducing his stake to 46,574 shares.

Expected impact

likely modest pressure as the market prices in the CFO's sale

Evidence & confidence

Form 4 is a primary source; the transaction size is modest but the CFO role makes it noteworthy.

Market effects

Minimal impact on the broader genetic testing sector.

Limited to U.S. investors tracking insider activity.

Low; the filing does not affect global markets.

Counterpoint

The sale could be a routine liquidity event unrelated to company outlook.

Key entities

  • Brophy Michael Burkes

    Chief Financial Officer of Natera, Inc.

  • Natera, Inc.

    Provider of genetic testing and reproductive health services.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.